Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03199586 · ClinicalTrials.gov registry record · Phase 1
Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor Malignancies
A Phase 1 study of Breast Cancer and Prostate Cancer, sponsored by Novita Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
- 3
- Study locations
NCT03199586: Completed Phase 1 study of Breast Cancer and Prostate Cancer, sponsored by Novita Pharmaceuticals.
NCT03199586 is a Phase 1 study of Breast Cancer and Prostate Cancer that has completed, run by Novita Pharmaceuticals. The registered enrollment target is 23 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03199586, a Phase 1 study of Breast Cancer and Prostate Cancer, has completed, sponsored by Novita Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
- 3
- Study locations
Study Summary
Phase 1 A: First-in-human phase 1 study to determine safety of NP-G2-044 when given orally on a daily X 28 days followed by a 14 day rest period.
Primary Outcome
Treatment related adverse events assessed by CTCAE V4.03
Conditions Studied
Interventions
- DRUG NP-G2-044
Study Locations (3)
Arizona
- HonorHealth Research Institute - Scottsdale
California
- City of Hope National Medical Center - Duarte
New York
- Memorial Sloan Kettering Hospital - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2017-12-21 |
| Est. Completion | 2020-05-07 |
| Phase | Phase 1 |
What the finished NCT03199586 record still lists
NCT03199586 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 23 participants, a relatively small participant target, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower).
The record links to 9 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which NP-G2-044 is the first listed.
NCT03199586 reports a single indexed study location in Arizona, California, New York.
Frequently Asked Questions
What is clinical trial NCT03199586 about?
NCT03199586 is a clinical study titled "Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor Malignancies". Phase 1 A: First-in-human phase 1 study to determine safety of NP-G2-044 when given orally on a daily X 28 days followed by a 14 day rest period.
What is the current status of trial NCT03199586?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2017-12-21. Estimated completion is 2020-05-07.
What conditions does trial NCT03199586 study?
This clinical trial studies the following conditions: Breast Cancer, Prostate Cancer, Lung Cancer, Colon Cancer, Liver Cancer.
What interventions are being tested in trial NCT03199586?
The interventions under investigation include: NP-G2-044 (DRUG).
Who is sponsoring clinical trial NCT03199586?
This trial is sponsored by Novita Pharmaceuticals, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03199586 being conducted?
This trial has 3 study locations across Arizona, California, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03199586's enrollment target sits among peer trials
23 1056th of 1224 higher than 163 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
VS-6766+Abema+Fulv in Met HR+/HER- BC
RECRUITING · Phase 1
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
Focused Ultrasound and Gemcitabine in Breast Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03616041 · 23 participants
Capsule Endoscopy for Severe Hematochezia
- NCT04348747 · 23 participants · Phase 2
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- NCT04587687 · 23 participants · Phase 2
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
- NCT04715022 · 23 participants · Phase 1
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI